• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Psychiatry  • Psychiatry, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Gen Psychiatry. 1998;55:643-644.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

IN THIS issue of the ARCHIVES, McDougle and colleagues¹ report on another interesting, placebo-controlled trial of psychotropic medication in the treatment of autism. Following their study of fluvoxamine,² McDougle and colleagues demonstrate the efficacy for risperidone in the treatment of severe behavioral problems frequently, but not invariably, found in persons with autistic disorder. These are important and valuable findings. So, with all this good news, what is the irony?

Since Kanner³ first named the disorder in 1943, there have been enormous advances in the study of autism. Among the most important has been the precise and internationally agreed on definition of the syndrome of autism. Yet ironically, the subjects in this study are imprecisely defined and the ascertainment of this clinical population is not well articulated. There is also a lack of clarity about the diagnoses, and thus it is unclear whether this population represents a minority of adults with . . . [Full Text of this Article]

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Risperidone Reduces Behavioral Symptoms of Autism in Adults
JWatch Psychiatry 1998;1998:8-8.
FULL TEXT